Analysis of global survival and risk factors for death in 509 systemic lupus erythematosus (SLE) patients;Análise de sobrevida global e fatores de risco para óbito em 509 pacientes com Lúpus Eritematoso Sistêmico (LES)

Revista Brasileira de Reumatologia

Volumn 44, Issue 3, 2004, Pages 198-205

  Appenzeller, Simone ^a   Costallat, Lilian Tereza Lavras ^a  

^a UNIVERSITY OF CAMPINAS   (Brazil)

Author keywords

Mortality; Risk factors; Survival; Systemic Lupus Erythematosus

Indexed keywords

EID: 77956681651     PISSN: 04825004     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Carbotte RM, Denburg SD, Denburg JA: Prevalence of cognitive impairment in systemic lupus erythematosus. J Nerv Ment Dis 174: 357-64, 1986.
2. Harvey AM: Systemic Lupus erythematosus: review of literature and clinical analysis of 138 cases. Medicine 33: 291-437, 1954.
3. Merrel M, Shulman E: Determination of prognosis in chronic disease, illustred by lupus erythematosus. J. Chronic Dis 1: 12-32, 1955.
4. Ganczareczyk L, Urowitz MB, Gladman DD: Latent lupus. J Rheumatol 16: 475-8, 1989.
5. Abu-Shakra M, Urowitz MB, Gladman DD, Gough J: Mortality studies in systemic lupus erythematosus. Results from a single center. I. Causes of death. J Rheumatol 22: 1259-64, 1995.
6. Gripenberg M, Helve T: Outcome of systemic lupus erythematosus. A study of 66 patients over 7 years with special reference to the predictive value of anti DNA determination. Scand J Rheumatol 20: 104-9, 1991.
7. Pistiner M, Wallace DJ, Nessim S, Metzger AL, Klinenberg JR: Lupus erythematosus in the 1980s: a survey of 570 patients. Semin Arthritis Rheum 21: 55-64, 1991.
8. Reveille JD, Bartolucci A, Alarcon GS: Prognosis in SLE: negative impact of increasing age in onset, black race and thrombocytopenia, as well as causes of death. Arthritis Rheum 33: 37-48, 1990.
9. Gladmann DD: Prognosis of systemic lupus erythematosus and factors that affect it. Curr Opin Rheumatol 4: 681-7, 1992.
10. Sato EI, Vieira AL, Porchini AC, et al: Fatores prognósticos no lúpus eritematoso sistêmico. Rev Bras Reumatol 35: 235-41, 1995.
11. Sibley JT, Olszynski WP, Decoteau WE, Sundaram MB: The incidence and prognosis of central nervous system disease in SLE. J Rheumatol 19: 47-52, 1992.
12. Hellmann DB: Fatal infection in systemic lupus erythematosus: the role of opportunistic organisms. Medicine 66: 341-8, 1987.
13. Tan EM, Cohen AS, Fries JF, et al: The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 25: 1271-7, 1982.
14. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J AM Sat Assoc 53: 457-81, 1953.
15. Cox DR: Regression models and life tables. J R Stat Soc 34: 187-202, 1972.
16. Fries JF, Weyl S, Holman HR: Estimating prognosis in systemic lupus erythematosus. Am J Med 57: 561-5, 1974.
17. Seleznick MJ, Fries JF: Variables associated with decreased survival in SLE. Semin Arthrits Rheum 21: 73-80, 1991.
18. Kaufman LD, Gomez-Reino JJ, Heinicke MH, Gorevic PD: Male lupus: retrospective analysis of the clinical and laboratory features of 52 patients, with a review of the literature. Semin Arthritis Rheum 18: 189-97, 1989.
19. Schaller J: Lupus in childhood. Clin Rheumatol 8: 219-50, 1982.
20. Tucker LB, Menon S, Schaller JG, Isenberg DA: Adult and childhood-onset SLE: a comparison of onset, clinical features, serology and outcome. Br J Rheumatol 34: 866-72, 1995.
21. Costallat LTL, Coimbra AMV: SLE: clinical and laboratory aspects related to age at disease. Clin Exp Rheumatol 12: 603-7, 1994.
22. Abu-Shakra M, Urowitz MB, Gladman DD, Gough J: Mortality studies in systemic lupus erythematosus. Results from a single center. II. Predictor variables for mortality. J Rheumatol 22: 1265-70, 1995.
23. Rothfield NF: Cardiopulmonar manifestations. In: Schur, Phed. The clinical management of SLE. Orlando, Grune & Startton, 113-22, 1983.
24. Wallace DJ, Podell T, Weiner J, Klinenberg JR, Forouzesh S, Dubois EL: Systemic lupus erythematosus--survival patterns. Experience with 609 patients. JAMA 245: 934-8, 1981.
25. Rothfield NF: SLE: clinical aspects and treatment. Arthritis and allied conditions, Philadelphia, L&F, 1155-77, 1993.
26. Manager K, Manger K, Repp R, et al: Definition of risk factors for death, end stage renal disease, and thromboembolic events in a monocentric cohort of 338 patients with systemic lupus erythematosus. Ann Rheum Dis 61:1065-70, 2002.
27. Spiera RF, Homel P, Spiera H: Long-term outcome in lupus nephritis. Ann Intern Med 137: 545-6, 2002.
28. Beaufils M, Kouki F, Mignon F, Camus JP, Morel-Maroger L, Richet G: Clinical significance of anti-Sm antibodies in systemic lupus erythematosus. Am J Med 74: 201-12, 1983.
29. Latorre LC: Caracterização tecidual e sorológica de complexos Sm e RNP na nefropatia lúpica, São Paulo, 1987. (Dissertação Mestrado- FMUSP).
30. Gulko PS, Reveille JD, Koopman WJ, Burgard SL, Bartolucci AA, Alarcon GS: Survival impact of autoantibodies in systemic lupus erythematosus. J Rheumatol 21: 224-8, 1994.
31. Borba EF, Bonfa E: Longterm beneficial effects of chloroquine diphosphate on lipoprotein profile in SLE patients with and without steroid treatment. J Rheumatol 4: 780-5, 2001.